RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC

oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]

AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA grants early access to experimental pancreatic cancer drug / 29 days

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks

Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 2 months

Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 2 months